{"id":127437,"date":"2026-09-08T08:03:04","date_gmt":"2026-09-08T08:03:04","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/127437\/"},"modified":"2026-09-08T08:03:04","modified_gmt":"2026-09-08T08:03:04","slug":"novartis-sees-another-setback-this-time-with-neuromuscular-drug","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/127437\/","title":{"rendered":"Novartis sees another setback, this time with neuromuscular drug"},"content":{"rendered":"

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.<\/p>\n

An experimental drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study, Novartis said Tuesday, the company\u2019s second major trial collapse<\/a> in a matter of days.\u00a0<\/p>\n

The two study flops will likely stoke concerns about Novartis\u2019 pipeline and its acquisition strategy as it navigates a major patent cliff, though the company did see a victory with a multiple sclerosis drug last week.\u00a0The stock was down by as much as 10% in early trading in Switzerland. <\/p>\n

The Phase 3 HARBOR trial was testing the drug del-desiran in a condition called myotonic dystrophy type 1, known as DM1, which causes progressive muscle stiffness and weakness. Novartis said the drug did not meet its primary endpoint of outperforming placebo on improving video hand opening time, or vHOT, a measure of the hand\u2019s ability to relax after squeezing.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…\n","protected":false},"author":2,"featured_media":127438,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[324,206,337,5113,339],"class_list":["post-127437","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-drug-development","tag-novartis","tag-pharmaceuticals","tag-rare-disease","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117234381957042306","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=127437"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127437\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/127438"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=127437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=127437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=127437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}